In patients with NASH, there was a declining trend observed in the expression of NR5A2, although no statistically significant differences were detected at either the transcriptional or protein level (Fig. 1A–C). The gene discussed is NR5A2; the disease is metabolic dysfunction-associated steatohepatitis.